Released Feb 26, 2019, after the close
10-K filed Feb 27, 2019, 58 days after period end · 0001564590-19-004596
Q4 2018 · 10-K
Revenue$59.57M$59.57M +36.7% vs Q4 2017+2.2% vs Q3 2018
Net Income-$65.49M-$65.49M N/M vs Q4 2017N/M vs Q3 2018
EPS Diluted-$0.50-$0.50 N/M vs Q4 2017N/M vs Q3 2018
Gross Profit$56,748,000+38.0%
Operating Incomederived-$67,275,000N/M
Operating Cash Flowderived-$39,079,000N/M
Free Cash Flowderived-$39,605,000N/M
Margins · derived
Gross margin95.3%+0.9 pt vs Q4 2017
Operating margin-112.9%+47.8 pt vs Q4 2017
Net margin-109.9%+48.2 pt vs Q4 2017
What the release said
The release
Same quarter
| Metric | Q4 2018 | Q4 2017 | Q4 2016 | Q4 2015 |
|---|---|---|---|---|
| Revenue | $59.57M | $43.56M | $11.96M | $17.00K |
| Net Income | -$65.49M | -$68.87M | -$78.70M | -$45.78M |
| EPS Diluted | -$0.50 | -$0.55 | -$0.65 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR